| 4.12 -0.08 (-1.9%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.32 | 1-year : | 6.22 |
| Resists | First : | 4.56 | Second : | 5.32 |
| Pivot price | 3.36  |
|||
| Supports | First : | 2.9 | Second : | 1.87 |
| MAs | MA(5) : | 4.26 |
MA(20) : | 3.08 |
| MA(100) : | 3.04 |
MA(250) : | 0 | |
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 84.5 |
D(3) : | 87.6 |
| RSI | RSI(14): 73.6 |
|||
| 52-week | High : | 7.25 | Low : | 1.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CPIX ] has closed below upper band by 28.4%. Bollinger Bands are 237.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.28 - 4.31 | 4.31 - 4.33 |
| Low: | 3.97 - 4.01 | 4.01 - 4.04 |
| Close: | 4.07 - 4.12 | 4.12 - 4.16 |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Tue, 23 Dec 2025
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above Two Hundred Day Moving Average - Time to Sell? - MarketBeat
Fri, 19 Dec 2025
Zacks Initiates Coverage of CPIX With Outperform Recommendation - Zacks Investment Research
Thu, 11 Dec 2025
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Shares Fly 26% But Investors Aren't Buying For Growth - Sahm
Mon, 08 Dec 2025
Cumberland (Nasdaq: CPIX) gets CMS price-linked J-code for Caldolor injection - Stock Titan
Tue, 04 Nov 2025
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH - PR Newswire
Tue, 28 Oct 2025
Cumberland Pharmaceuticals (Nasdaq: CPIX) to Report Q3 2025 Results, Hosting Investor Call - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 15 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 41.6 (%) |
| Held by Institutions | 22.9 (%) |
| Shares Short | 25 (K) |
| Shares Short P.Month | 50 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.75 |
| Profit Margin | -8.1 % |
| Operating Margin | -23.8 % |
| Return on Assets (ttm) | -2.9 % |
| Return on Equity (ttm) | -13.3 % |
| Qtrly Rev. Growth | -8.7 % |
| Gross Profit (p.s.) | 2.33 |
| Sales Per Share | 2.75 |
| EBITDA (p.s.) | 0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -17.17 |
| PEG Ratio | 0 |
| Price to Book value | 2.35 |
| Price to Sales | 1.49 |
| Price to Cash Flow | 9.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|